CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...